6 days ago
Pharma Leaders Seek Faster Trials and Support for Innovation
Pharma leaders say India could make it easier to test new medicines.
Kiran Mazumdar-Shaw said special research hospitals could help companies run early drug trials in India.
She said some companies hold their first tests on people in other countries because approvals at home can take a long time.
She also wants the government to help pay for some life-saving medicines.
That could encourage companies to work on treatments for illnesses that lack good options.
Dilip Shanghvi said developing new medicines is risky and can take years to bring returns.
Glenn Saldanha said companies can pursue innovation through their own research, partnerships, or acquisitions.
He said a Glenmark deal with AbbVie could be worth nearly $2 billion if milestones are reached.
Biocon executive chair Kiran Mazumdar-Shaw urged the government to accredit research hospitals for early-stage drug trials.
She said lengthy domestic approval processes have led companies to conduct first-in-human trials abroad.
Mazumdar-Shaw proposed government reimbursement for life-saving medicines to encourage investment in treatments for unmet needs.
Sun Pharma chair Dilip Shanghvi said innovation requires companies to accept high risks and wait years for returns.
Glenmark chief Glenn Saldanha cited licensing and acquisitions as routes to innovation, including a deal with AbbVie worth up to nearly $2 billion with milestones.
- Who
- Biocon's Kiran Mazumdar-Shaw, Sun Pharma's Dilip Shanghvi and Glenmark Pharma's Glenn Saldanha.
- What
- Pharma executives called for faster early-stage trials and discussed government support and business strategies for developing innovative medicines.
- Where
- At the IFQM conference; the country is identified as India.
- When
- At the IFQM conference on Monday; the article does not specify a date.
- Why
- They said lengthy trial approvals, limited support and the risks of innovation affect companies' ability and willingness to develop new medicines.
Calls for greater support
Industry-led investment paths
Government role in trials and medicine access
Calls for greater support
Mazumdar-Shaw called for accredited research hospitals to make early-stage trials easier in India and proposed public reimbursement for life-saving medicines.
Industry-led investment paths
The article presents Shanghvi and Saldanha emphasizing companies' investment choices, risk-taking, licensing and acquisitions; it does not report them taking a position against government support.
Routes to innovation
Calls for greater support
Saldanha said some companies may develop innovation through their own research.
Industry-led investment paths
Saldanha said other companies could use licensing deals or acquisitions, while Shanghvi described Sun Pharma's Organon acquisition as a way to build global launch capabilities.
Key facts
- Trial proposal
- Mazumdar-Shaw urged the government to accredit research hospitals with strong ethics committees for first-in-human trials.
- Reimbursement proposal
- She suggested a government-reimbursed programme for life-saving medicines.
- Innovation risk
- Shanghvi described innovation investment as high-risk and high-reward, with returns potentially taking years.
- Sun Pharma target
- The article says the share of innovative medicines in Sun's business is expected to rise from about 22% to 30%.
- Glenmark-AbbVie deal
- The licensing deal included $700 million upfront and could reach nearly $2 billion with milestones.
- Industry outlook
- Saldanha said significant activity in innovation could occur over the next 5–10 years.
Quotes
Kiran Mazumdar-Shaw
Biocon executive chairman
“Be confident, invest in innovation. The return will come after some years. It is a high-risk, high-reward kind of investment”
financialexpress.com
“Companies have tended to do their first-in-human trials outside India because India is tedious and long drawn out”
financialexpress.com
Sources
Related news
Indian Biotech Leaders Call for Patient Capital, Policy Predictability
India’s CRDMO Shift Puts Jubilant and Sai in Focus
Congress Questions Centre Over High Prices of Life-Saving Medicines
India’s New Digital Drug System Attracts Twelve Bids
GST Council May Back 90% Pharma Refunds in Law
Kerala High Court Opens Patent Path for Costly Drugs
Kiran Mazumdar-Shaw Calls Bengaluru Traffic a Warning Signal
AI Risks and Bubble Fears Temper Mood at Singapore Forums
Geetanjali Kirloskar Receives FKCCI’s Sir M. Visvesvaraya Award
Fendi’s Rs 8.3 Lakh Bag Draws Cultural Appropriation Outrage
